Showing 1 to 15 of 59 entries
TOP PICK
It is in the health care field for animals. $20 billion is spent for over -the-counter medicine and supplies for pets. There is no pricing pressure from insurance companies since most expenditures come from out-of-pocket. Also there are faster trial periods and they usually start from a human base. Great products coming. Has great cash flow, a strong balance sheet and very little debt. Buy 12 Hold 2 Sell 0 (Analysts’ price target is $223.50)
Consumer Products
PAST TOP PICK
(A Top Pick Aug 12/21, Down 18%) Still likes it, likes the animal healthcare industry. Pet spending continues to grow and there's little competition in this space. It tends to trade at a valuation premium, but still overall attractive.
Consumer Products
PAST TOP PICK
(A Top Pick Aug 19/21, Down 15%) Stopped out. Really great franchise in vet pharmaceuticals, which are growing quite quickly. Big pandemic pet boom came off the boil a bit, so he pivoted to biotech.
Consumer Products
BUY
Had a good earnings report yesterday, narrowing the range for earnings and total revenue. Companion animal business is up 14% and they have many products in the pipeline.
Consumer Products
BUY
Healthcare has done very well. She just added Zoetis, pet health. One in 5 households adopted a dog in the last 2 years during Covid. Zoetis has held up well relatively to the market.
Consumer Products
BUY
Zoetis is new to him. They are in pet health across many species. He met management and was impressed. Pets are recession-proof sector. Americans own 110 million cats--who knew? Fascinating company.
Consumer Products
WAIT
Regarding the price to sales part of the question he feels this metric is controversial as it is hard to determine whether the price is too high or too low. It is a very good company and he bought the IPO spin-off from Pfizer. It is in animal health and there are concerns over its valuation. Many similar companies in human health trade at lower valuations and are growing nicely. It has outperformed for a long time so it may be ready for a break. Wait and watch for people to gravitate to animal health.
Consumer Products
TOP PICK
Livestock segment has been challenged the last 2 years, but it's a consistent business over time. Pet side has grown incredibly. Great backlog of drugs, which can come to market faster than drugs for humans. With the pullback, good time to buy. Yield is 0.80%. (Analysts’ price target is $235.45)
Consumer Products
PAST TOP PICK
(A Top Pick May 18/21, Down 1%) Continues to like it and will buy at these levels. Pets are almost 60% of their business and growing nicely. Pet owners are getting younger, who spend more on their pets. Also, pets are aging and so require medications which benefits ZTS. Pet spending endures during recessions, too. But the stock got ahead of itself and has fallen back now. Earnings are good, but the company reduced guidance. Revenue growth remains 9-10% and EPS 10-13%, which she believes in.
Consumer Products
BUY
They report Thursday and he expects consistent, strong numbers. It's very well run.
Consumer Products
TOP PICK
Livestock growth is slow but consistent. Pet business has shown exponential growth. Few generic pet drugs, plus drugs get to market faster. Once pets becomes a member of your family, owners can't stop spending money on them. Yield is 0.69%. (Analysts’ price target is $245.73)
Consumer Products
TOP PICK
Leading player in animal health. Likes healthcare, especially in higher interest rate environment. Growth in pet companion side. Pet ownership demographic is getting younger, and they spend more. R&D cycle is less onerous than for humans, patent life is longer, no strong generic competitor. Expects 10% revenue growth, double-digit earnings growth. Yield is 0.69%. (Analysts’ price target is $245.73)
Consumer Products
PAST TOP PICK
(A Top Pick Mar 04/21, Up 34%) Great business that will continue to grow. Animal healthcare. Tough recently, but will get back to previous levels in next couple of years. No generic drugs to compete, and they're easier to bring to market. 2B in free cashflow, great balance sheet. Great products in pipeline. He's buying here.
Consumer Products
TOP PICK
World's largest in animal health. Dominant player. Petcare (tremendous growth) and livestock (low growth, low margin). Nothing has fundamentally changed in its business for medium-long term growth. Caught up in the macro rotation. Expanding diagnostics business over next 1-2 years. You pay up for it, but unique position. Yield is 0.65%. (Analysts’ price target is $245.54)
Consumer Products
BUY on WEAKNESS
It has pulled back 10% YTD. It trades at a premium PE given its unique positioning in animal healthcare; it executes very well. She likes this sector. She's been adding shares during this pullback.
Consumer Products
Showing 1 to 15 of 59 entries

Zoetis Inc(ZTS-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 10

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 10

Stockchase rating for Zoetis Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Zoetis Inc(ZTS-N) Frequently Asked Questions

What is Zoetis Inc stock symbol?

Zoetis Inc is a American stock, trading under the symbol ZTS-N on the New York Stock Exchange (ZTS). It is usually referred to as NYSE:ZTS or ZTS-N

Is Zoetis Inc a buy or a sell?

In the last year, 10 stock analysts published opinions about ZTS-N. 10 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Zoetis Inc.

Is Zoetis Inc a good investment or a top pick?

Zoetis Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Zoetis Inc.

Why is Zoetis Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Zoetis Inc worth watching?

10 stock analysts on Stockchase covered Zoetis Inc In the last year. It is a trending stock that is worth watching.

What is Zoetis Inc stock price?

On 2022-09-28, Zoetis Inc (ZTS-N) stock closed at a price of $152.26.